All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide

C1S (riliprubart Biosimilar) Recombinant Monoclonal Antibody

Datasheet
Code CSB-RA003657MB1HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
P09871
Target Names
C1S
Alternative Names
Basic proline rich peptide IB 1 antibody; C1 esterase antibody; C1S antibody; C1S_HUMAN antibody; Complement C1s subcomponent antibody; Complement C1s subcomponent heavy chain antibody; Complement C1s subcomponent light chain antibody; Complement component 1 s subcomponent antibody; Complement component 1 subcomponent s antibody; FLJ44757 antibody
Species Reactivity
Human
Immunogen
Recombinant Human C1S protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS，pH7.4
Form
Liquid
Troubleshooting and FAQs
Antibody FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
In stock
Description

This recombinant monoclonal antibody is a research-grade biosimilar to riliprubart, designed for research involving C1S (complement component 1s), a serine protease critical to the classical complement pathway. C1S functions as part of the C1 complex, where it cleaves C4 and C2 to initiate the complement cascade, a key component of innate immunity. Dysregulated C1S activity contributes to various complement-mediated disorders, including autoimmune diseases, transplant rejection, and conditions involving excessive inflammation. Aberrant classical pathway activation has been implicated in cold agglutinin disease, antibody-mediated rejection, and certain inflammatory neuropathies.

Riliprubart represents a therapeutic antibody developed to selectively inhibit C1S, thereby modulating classical complement activation while preserving alternative pathway function. As a research-grade biosimilar, this antibody enables investigators to explore C1S biology, validate complement inhibition strategies, and study disease mechanisms where classical pathway dysregulation plays a pathogenic role. It serves as a valuable tool for immunology research, complement pathway studies, and preclinical investigations into complement-targeted therapeutic approaches.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Related Products

C1S Antibodies

C1S Proteins

C1S ELISA kits

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4.
Gene References into Functions
  1. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. PMID: 24695853
  2. Data indicate that complement C1s mRNA level was low in ICR-derived glomerulonephritis (ICGN) mice liver as compared with age-matched ICR mice. PMID: 23989031
  3. A molecular switch governs the interaction between the human complement protease C1s and its substrate, complement C4. PMID: 23592783
  4. Four positively charged amino acids on the serine protease domain appear to form a catalytic exosite that is required for efficient cleavage of C4 in the classical pathway of complement. PMID: 22855709
  5. Detailed mapping of post-translational modifications and insights into the C1r/C1s binding sites. PMID: 20008834
  6. Interaction with the prime side residues at the cleavage point in C1s enhances the affinity of the enzyme for complement 2 and complement 4 substrates; these prime subsite residues mediate positive cooperativity in the cleavage of the substrate. PMID: 14674770
  7. full specificity of the enzyme using a randomized phage display library PMID: 16169853
  8. There are splice variants of C1s mRNA transcripts in normal human cells PMID: 18062908

Show More

Hide All

Involvement in disease
Complement component C1s deficiency (C1SD); Ehlers-Danlos syndrome, periodontal type, 2 (EDSPD2)
Protein Families
Peptidase S1 family
Database Links

HGNC: 1247

OMIM: 120580

KEGG: hsa:716

STRING: 9606.ENSP00000328173

UniGene: Hs.458355

Promotions
Reward For Reviews
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*